Tags

Type your tag names separated by a space and hit enter

Pharmacology of vertigo/nystagmus/oscillopsia.
Curr Opin Neurol. 2005 Feb; 18(1):11-4.CO

Abstract

PURPOSE OF REVIEW

To describe recent developments in the pharmacological treatment of vertigo and nystagmus while focusing on vestibular neuritis, Meniere's disease, downbeat nystagmus, periodic alternating nystagmus, acquired pendular nystagmus, and superior oblique myokymia.

RECENT FINDINGS

In the last 2 years several studies have been published on possible pharmacological treatment options for nystagmus and oscillopsia. In the treatment of vestibular neuritis two studies showed that cortisone treatment was effective for restoring labyrinthine function. This benefit seems more likely if treatment is started within the first 2 days of onset. For recurrent vertigo attacks due to Meniere's disease, the titration technique with daily or weekly doses of intratympanic gentamicin until onset of vestibular symptoms, change in vertigo or hearing loss rated best for complete vertigo control. A new pharmacological treatment option for downbeat nystagmus is the administration of potassium channel blockers (e.g. 4-aminopyridine). They are thought to reinforce the inhibitory action of cerebellar Purkinje cells. Several case reports have proven the beneficial effect of baclofen on periodic alternating nystagmus, of gabapentin and memantine on acquired pendular nystagmus, and of carbamazepine and gabapentin on superior oblique myokymia.

SUMMARY

There have been several new developments in the treatment of nystagmus and vertigo over the last 2 years. These include potassium channel blockers for the treatment of downbeat nystagmus, early cortisone treatment to improve recovery of the labyrinth function in vestibular neuritis, and intratympanic gentamicin treatment for Meniere's disease. Other pharmacological treatment options are baclofen for periodic alternating nystagmus, gabapentin and memantine for acquired pendular nystagmus, and carbamazepine for superior oblique myokymia.

Authors+Show Affiliations

Department of Neurology, University of Munich, Munich, Germany. astraube@brain.nefo.med.uni-muenchen.de

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15655396

Citation

Straube, Andreas. "Pharmacology of Vertigo/nystagmus/oscillopsia." Current Opinion in Neurology, vol. 18, no. 1, 2005, pp. 11-4.
Straube A. Pharmacology of vertigo/nystagmus/oscillopsia. Curr Opin Neurol. 2005;18(1):11-4.
Straube, A. (2005). Pharmacology of vertigo/nystagmus/oscillopsia. Current Opinion in Neurology, 18(1), 11-4.
Straube A. Pharmacology of Vertigo/nystagmus/oscillopsia. Curr Opin Neurol. 2005;18(1):11-4. PubMed PMID: 15655396.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacology of vertigo/nystagmus/oscillopsia. A1 - Straube,Andreas, PY - 2005/1/19/pubmed PY - 2005/9/16/medline PY - 2005/1/19/entrez SP - 11 EP - 4 JF - Current opinion in neurology JO - Curr Opin Neurol VL - 18 IS - 1 N2 - PURPOSE OF REVIEW: To describe recent developments in the pharmacological treatment of vertigo and nystagmus while focusing on vestibular neuritis, Meniere's disease, downbeat nystagmus, periodic alternating nystagmus, acquired pendular nystagmus, and superior oblique myokymia. RECENT FINDINGS: In the last 2 years several studies have been published on possible pharmacological treatment options for nystagmus and oscillopsia. In the treatment of vestibular neuritis two studies showed that cortisone treatment was effective for restoring labyrinthine function. This benefit seems more likely if treatment is started within the first 2 days of onset. For recurrent vertigo attacks due to Meniere's disease, the titration technique with daily or weekly doses of intratympanic gentamicin until onset of vestibular symptoms, change in vertigo or hearing loss rated best for complete vertigo control. A new pharmacological treatment option for downbeat nystagmus is the administration of potassium channel blockers (e.g. 4-aminopyridine). They are thought to reinforce the inhibitory action of cerebellar Purkinje cells. Several case reports have proven the beneficial effect of baclofen on periodic alternating nystagmus, of gabapentin and memantine on acquired pendular nystagmus, and of carbamazepine and gabapentin on superior oblique myokymia. SUMMARY: There have been several new developments in the treatment of nystagmus and vertigo over the last 2 years. These include potassium channel blockers for the treatment of downbeat nystagmus, early cortisone treatment to improve recovery of the labyrinth function in vestibular neuritis, and intratympanic gentamicin treatment for Meniere's disease. Other pharmacological treatment options are baclofen for periodic alternating nystagmus, gabapentin and memantine for acquired pendular nystagmus, and carbamazepine for superior oblique myokymia. SN - 1350-7540 UR - https://www.unboundmedicine.com/medline/citation/15655396/Pharmacology_of_vertigo/nystagmus/oscillopsia_ L2 - https://doi.org/10.1097/00019052-200502000-00004 DB - PRIME DP - Unbound Medicine ER -